Lehigh University, Bethlehem, PA 18015, USA.
J Atten Disord. 2012 Apr;16(3):202-20. doi: 10.1177/1087054711427299. Epub 2011 Dec 12.
To evaluate stimulant medication on symptoms and functioning for college students with ADHD using double-blind, placebo-controlled, crossover design.
Participants included 24 college students with ADHD and 26 college students without psychopathology. Lisdexamfetamine dimesylate (LDX) was examined for ADHD participants over five weekly phases (no-drug baseline, placebo, 30-, 50-, and 70-mg LDX per day). Self-report rating scales of functioning and direct assessment of ADHD symptoms, verbal learning/memory, and adverse side effects were collected (baseline only for control students).
LDX was associated with large reductions in ADHD symptoms and improvement in executive functioning along with smaller effects for psychosocial functioning. Reduction in ADHD symptoms was found for 86.4% of participants; however, large differences in symptoms and executive functioning remained relative to controls.
LDX is a safe, efficacious treatment for symptom relief in college students with ADHD. Research documenting medication effects on academic functioning and evaluating psychosocial/educational interventions is needed.
采用双盲、安慰剂对照、交叉设计，评估兴奋剂药物对大学生注意缺陷多动障碍（ADHD）症状和功能的影响。
参与者包括 24 名患有 ADHD 的大学生和 26 名没有精神病理学的大学生。对 ADHD 参与者进行了为期五周的 lisdexamfetamine dimesylate（LDX）药物治疗（无药物基线、安慰剂、30mg、50mg 和 70mg LDX 每日剂量）。收集了功能的自我报告评定量表和 ADHD 症状、言语学习/记忆以及不良反应的直接评估（仅对对照组的学生进行基线评估）。
LDX 与 ADHD 症状的大量减少以及执行功能的改善相关，对社会心理功能的影响较小。86.4%的参与者的 ADHD 症状得到缓解；然而，与对照组相比，症状和执行功能仍存在较大差异。
LDX 是治疗大学生 ADHD 症状的一种安全有效的方法。需要研究药物对学业功能的影响，并评估社会心理/教育干预措施。
